Coronary thrombolysis in dogs with intravenously administered human pro-urokinase. 1985

D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen

Coronary thrombolysis was induced by infusion of highly purified human pro-urokinase isolated from a transformed kidney cell line (ACHN) or by infusion of urokinase of urinary origin in anesthetized dogs with 1-hr-old clots in the left anterior descending coronary artery. The clots were induced with a copper coil and thrombolysis was detected by repeat coronary angiography. Intravenous infusion of pro-urokinase at a rate of 10 micrograms/kg/min for 30 min in two dogs did not induce thrombolysis, which was only obtained after 8 and 15 min of its subsequent intracoronary administration. Intravenous infusion of pro-urokinase at a rate of 20 micrograms/kg/min for 30 min in four dogs induced coronary thrombolysis within 23 +/- 2 min (mean +/- SEM). This was not associated with systemic fibrinolytic activation because the alpha 2-antiplasmin and fibrinogen levels did not decrease. Intravenous infusion of urokinase at a rate of 10 micrograms/kg/min for 30 min elicited thrombolysis in four of seven dogs within an average of 19 +/- 2 min. In the other three dogs thrombolysis was only obtained within 11 +/- 3 min of its subsequent intracoronary infusion. Administration of urokinase was associated with systemic fibrinolytic activation as evidenced by a decrease of alpha 2-antiplasmin to about 10% and of fibrinogen to 43 +/- 13% of the preinfusion value. It is concluded that intravenous infusion of pro-urokinase at a sufficiently high rate produces coronary thrombolysis without systemic fibrinolysis in dogs.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D003331 Coronary Vessels The veins and arteries of the HEART. Coronary Arteries,Sinus Node Artery,Coronary Veins,Arteries, Coronary,Arteries, Sinus Node,Artery, Coronary,Artery, Sinus Node,Coronary Artery,Coronary Vein,Coronary Vessel,Sinus Node Arteries,Vein, Coronary,Veins, Coronary,Vessel, Coronary,Vessels, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen
April 1989, Circulation,
D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen
January 1988, Klinische Wochenschrift,
D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen
March 1986, Annals of internal medicine,
D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen
March 1984, Circulation,
D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen
July 1994, Nihon rinsho. Japanese journal of clinical medicine,
D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen
January 1987, Journal of cardiovascular pharmacology,
D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen
July 1992, Catheterization and cardiovascular diagnosis,
D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen
April 2003, Nihon rinsho. Japanese journal of clinical medicine,
D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen
August 1987, The American journal of medicine,
D Collen, and D Stump, and F van de Werf, and I K Jang, and M Nobuhara, and H R Lijnen
December 1966, Metabolism: clinical and experimental,
Copied contents to your clipboard!